RSV vaccine (GSK3003891A) formulation 1

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Respiratory Syncytial Virus Infections

Phase 2

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

CompletedNCT02956837

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2016-11-10End: 2018-02-05Updated: 2019-07-02

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

WithdrawnNCT03191383

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2017-07-11End: 2017-07-14Updated: 2018-10-15

Related Papers

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

Human Vaccines & Immunotherapeutics2020-01-172 citations

Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial

The Journal of Infectious Diseases2019-07-3124 citations